Author(s): Jobin B; Phillips NA; Frasnelli J; Boller B;

BackgroundOlfactory identification decline is a known early marker of Alzheimer's disease and is already present at the mild cognitive impairment (MCI) stage. While being linked with episodic memory, its predictive value for cognitive performance and distinguishing between clinical stages remains unclear.ObjectiveThis study examined (1) the predictive ...

Article GUID: 40944318

Author(s): Hosseininasabnajar F; Kakinami L;

Loss of brain tissues and cognitive abilities are natural processes of aging, but longitudinal studies are limited. We explored the longitudinal association between global and regional brain measures with cognitive abilities among individuals with normal cognitive status, mild cognitive impairment, and Alzheimer's Disease, including those with stable ...

Article GUID: 40739300

Author(s): Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM;

White matter hyperintensities (WMHs) are neuroimaging markers widely interpreted as caused by cerebral small vessel disease, yet emerging evidence suggests that a subset may have a neurodegenerative etiology. Current imaging methods have lacked the specificity to disentangle biological processes ...

Article GUID: 40585093

Author(s): Silva MCJD; Pinto AMV; Balthar MA; Correa ABA; Bhattacharyya D; Simas ABC; Kuca K; Forgione P; França TCC; Cavalcante SFA; Kitagawa DAS;

Given the recent deployment of nerve agents as a method of warfare and in targeted assassinations, the development of robust, broad-spectrum medical countermeasures is essential. Our research group has synthesized isatin-pyridine oxime hybrids that have previously demonstrated the ability to resc ...

Article GUID: 40516590

Author(s): Sanami S; Intzandt B; Huck J; Villeneuve S; Iturria-Medina Y; Gauthier CJ; Prevent-Ad Research Group None;

Alzheimer's disease (AD) is a complex disease that involves complex interactions between protein biomarkers such as amyloid beta (Aß) and tau, neurodegeneration, cerebrovascular health and inflammation. However, how these factors interact, especially in the early phases of disease development ...

Article GUID: 40347524

Author(s): Pellerin S; Houzé B; Bedetti C; Phillips N; Brambati SM;

BackgroundMild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD) for many individuals, is accompanied by widespread connected speech (CS) changes (e.g., shorter CS samples, mention of fewer semantic content units, lower syntactic complexity). Nevertheless, findings on CS in MCI are heterogeneous. This heterogeneity, combined wi ...

Article GUID: 40232260

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139

Author(s): Páez A; Gillman SO; Dogaheh SB; Carnes A; Dakterzada F; Barbé F; Dang-Vu TT; Ripoll GP;

Introduction: Changes in sleep physiology can predate cognitive symptoms by decades in persons with Alzheimer's disease (AD), but it remains unclear which sleep characteristics predict cognitive and neurodegenerative changes after AD onset. Methods: Using data from a prospective cohort of mild to moderate AD (n = 60), we analyzed non-rapid eye moveme ...

Article GUID: 39878233

Author(s): Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello ...

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles ( ...

Article GUID: 39636028

Author(s): Caballero HS; McFall GP; Gee M; MacDonald S; Phillips NA; Fogarty J; Montero-Odasso M; Camicioli R; Dixon RA;

Background: Alzheimer's disease (AD) and Lewy body disease (LBD) are characterized by early and gradual worsening perturbations in speeded cognitive responses. Objective: Using simple and choice reaction time tasks, we compared two indicators of cognitive speed within and across the AD and L ...

Article GUID: 38875040

Author(s): Arsenio Páez, Emmanuel Frimpong, Melodee Mograss, Thien Thanh Dang-Vu

Sleep loss is associated with reduced health and quality of life, and increased risk of Alzheimer's disease and related dementias. Up to 66% of persons with Alzheimer's disease and related dementias experience poor sleep, which can predict or accelerate the progression of cognitive decline. Exercise is a widely accessible intervention for poor ...

Article GUID: 38462491